Histologic Ex Vivo Validation of the [<sup>18</sup>F]SITATE Somatostatin Receptor PET Tracer
Radiolabeled somatostatin analogs (SSAs), such as [<sup>68</sup>Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [<sup>18</sup>F]SITATE presents a promising alternative, offering the advantage of a longer half-life than <sup>68</sup>Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [<sup>18</sup>F]SITATE. <b>Methods:</b> This study retrospectively included 47 patients (57% male; mean age, 66.9 ± 14.9 y) with histologically confirmed well-differentiated neuroendocrine neoplasms who underwent [<sup>18</sup>F]SITATE PET followed by surgery within 4 mo. Lesion uptake was quantified using SUV<sub>mean</sub>, SUV<sub>peak</sub>, SUV<sub>max</sub>, and tumor-to-liver ratio (TLR). Histologic somatostatin receptor (SSTR) type 2 expression was determined using histological scores (H-scores), with thresholds defining SSTR scores 1-3. The accuracy of PET imaging for preoperative metastatic detection was evaluated against surgical histology. <b>Results:</b> PET imaging demonstrated a significant correlation between [<sup>18</sup>F]SITATE uptake (SUV<sub>mean</sub> and TLR) and SSTR type 2 H-scores (<i>r</i> = 0.618 and 0.622, respectively; <i>P</i> < 0.0001). SSTR score 3 correlated with increased SUV<sub>mean</sub> and TLR (<i>P</i> < 0.0001). Among 35 patients with primary resection and lymphadenectomy, PET achieved a sensitivity of 73.9% and specificity of 100%. <b>Conclusion:</b> [<sup>18</sup>F]SITATE PET imaging strongly correlates with histologic SSTR expression, demonstrating utility in staging and guiding therapeutic decisions in neuroendocrine neoplasms. This <sup>18</sup>F-labeled tracer shows specificity comparable to historical [<sup>68</sup>Ga]Ga-DOTA SSA data, whereas an increase in sensitivity for the detection of locoregional metastases appears possible. Further head-to-head comparisons of [<sup>18</sup>F]SITATE with traditional [<sup>68</sup>Ga]Ga-DOTA SSA and histologic validation are warranted to optimize its diagnostic accuracy and clinical impact.
Authors
- Gerald Reischl (ORCID: https://orcid.org/0000-0003-3961-116X)
- Sven Mattern (ORCID: https://orcid.org/0000-0001-7362-0209)
- Konstantin Nikolaou (ORCID: https://orcid.org/0000-0003-2668-7325)
- Christian la Fougère (ORCID: https://orcid.org/0000-0001-7519-0417)
- Silvio Nadalin (ORCID: https://orcid.org/0000-0001-8803-6670)
- Nils Florian Trautwein (ORCID: https://orcid.org/0000-0003-3397-6299)
- Ralf Schirrmacher (ORCID: https://orcid.org/0000-0002-7098-3036)
- Volker Steger
- Johannes Schwenck (ORCID: https://orcid.org/0000-0002-2627-4048)
- Martina Hinterleitner (ORCID: https://orcid.org/0000-0001-7137-0541)
- Stephan Singer (ORCID: https://orcid.org/0000-0003-4775-6609)
Institutions
- Siemens (Germany) (DE)
- University of Alberta (CA)
- German Cancer Research Center (DE)
- European Neuroendocrine Tumor Society (DE)
- STZ eyetrial (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-05-22
- DOI
- https://doi.org/10.2967/jnumed.125.269619
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35